MA29612B1 - Composes et methodes de modulation de la kinase et instructions afferentes - Google Patents
Composes et methodes de modulation de la kinase et instructions afferentesInfo
- Publication number
- MA29612B1 MA29612B1 MA30548A MA30548A MA29612B1 MA 29612 B1 MA29612 B1 MA 29612B1 MA 30548 A MA30548 A MA 30548A MA 30548 A MA30548 A MA 30548A MA 29612 B1 MA29612 B1 MA 29612B1
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- methods
- related instructions
- modulating kinase
- raf
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 3
- 108060006633 protein kinase Proteins 0.000 abstract 3
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 abstract 1
- 101150113474 MAPK10 gene Proteins 0.000 abstract 1
- 101150031398 MAPK9 gene Proteins 0.000 abstract 1
- 101150101215 Mapk8 gene Proteins 0.000 abstract 1
- 101100381978 Mus musculus Braf gene Proteins 0.000 abstract 1
- 230000001594 aberrant effect Effects 0.000 abstract 1
- -1 c-Raf-1 Proteins 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
- C07C37/62—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by introduction of halogen; by substitution of halogen atoms by other halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/24—Halogenated derivatives
- C07C39/26—Halogenated derivatives monocyclic monohydroxylic containing halogen bound to ring carbon atoms
- C07C39/27—Halogenated derivatives monocyclic monohydroxylic containing halogen bound to ring carbon atoms all halogen atoms being bound to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/673—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
- C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
- C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
- C07C47/56—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing hydroxy groups
- C07C47/565—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing hydroxy groups all hydroxy groups bound to the ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
- C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
Abstract
Composés actifs sur les protéines kinases, ainsi que méthodes d'utilisation de ces composés pour le traitement de pathologies et de symptômes associés à une activité aberrante des protéines kinases, y compris les kinases B-Raf, c-Raf-1, Fms, Jnk1, Jnk2, Jnk3 et Kit, ainsi que toutes mutations de celles-ci.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69296005P | 2005-06-22 | 2005-06-22 | |
US73152805P | 2005-10-28 | 2005-10-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA29612B1 true MA29612B1 (fr) | 2008-07-01 |
Family
ID=37033831
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA30548A MA29612B1 (fr) | 2005-06-22 | 2008-01-07 | Composes et methodes de modulation de la kinase et instructions afferentes |
Country Status (35)
Country | Link |
---|---|
US (10) | US7863288B2 (fr) |
EP (3) | EP3088400A1 (fr) |
JP (1) | JP5007304B2 (fr) |
KR (1) | KR101125919B1 (fr) |
CN (3) | CN102603581B (fr) |
AR (2) | AR054624A1 (fr) |
AT (1) | ATE518860T1 (fr) |
AU (1) | AU2006261993B2 (fr) |
BR (1) | BRPI0611863B1 (fr) |
CA (1) | CA2613015C (fr) |
CR (2) | CR9677A (fr) |
CY (2) | CY1111996T1 (fr) |
DE (1) | DE122012000043I1 (fr) |
DK (2) | DK2395004T3 (fr) |
EC (1) | ECSP088121A (fr) |
ES (2) | ES2565992T3 (fr) |
HK (2) | HK1114610A1 (fr) |
HU (2) | HUE027370T2 (fr) |
IL (1) | IL188248A (fr) |
LU (1) | LU92035I2 (fr) |
MA (1) | MA29612B1 (fr) |
MX (1) | MX2007016463A (fr) |
MY (2) | MY153898A (fr) |
NO (2) | NO333913B1 (fr) |
NZ (1) | NZ565255A (fr) |
PE (1) | PE20070100A1 (fr) |
PL (2) | PL2395004T3 (fr) |
PT (1) | PT1893612E (fr) |
RS (1) | RS52010B (fr) |
RU (3) | RU2565071C2 (fr) |
SI (2) | SI2395004T1 (fr) |
TW (3) | TWI522337B (fr) |
UA (1) | UA95244C2 (fr) |
WO (2) | WO2007002325A1 (fr) |
ZA (4) | ZA200711152B (fr) |
Families Citing this family (413)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL1696920T3 (pl) | 2003-12-19 | 2015-03-31 | Plexxikon Inc | Związki i sposoby opracowywania modulatorów Ret |
ATE508129T1 (de) | 2004-03-30 | 2011-05-15 | Vertex Pharma | Als inhibitoren von jak und anderen proteinkinasen geeignete azaindole |
US7498342B2 (en) | 2004-06-17 | 2009-03-03 | Plexxikon, Inc. | Compounds modulating c-kit activity |
JP4834553B2 (ja) | 2004-09-17 | 2011-12-14 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 医薬組成物 |
BRPI0610066A2 (pt) | 2005-05-17 | 2010-05-25 | Plexxikon Inc | compostos que modulam atividade de c-kit e c-fms e usos para estes |
BRPI0611863B1 (pt) | 2005-06-22 | 2021-11-23 | Plexxikon, Inc | Composto, bem como composição e kit compreendendo o mesmo, composto intermediário na preparação do mesmo, método para tratamento e uso do mesmo |
EP2251341A1 (fr) | 2005-07-14 | 2010-11-17 | Astellas Pharma Inc. | Hétérocycles inhibiteurs de Janus kinase-3 |
JP5071374B2 (ja) | 2005-07-14 | 2012-11-14 | アステラス製薬株式会社 | ヘテロ環ヤヌスキナーゼ3阻害剤 |
JP4989476B2 (ja) | 2005-08-02 | 2012-08-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質の効果を検定する方法 |
EP1938842A4 (fr) * | 2005-09-01 | 2013-01-09 | Eisai R&D Man Co Ltd | Procédé de préparation de composition pharmaceutique ayant une meilleure capacite de désintégration |
PT3184526T (pt) | 2005-12-13 | 2018-12-19 | Incyte Holdings Corp | Derivados de pirrolo[2,3-d]pirimidina como inibidores da cinase janus |
BRPI0722364A2 (pt) | 2006-01-17 | 2011-08-16 | Vertex Pharma | azaindóis, composição farmacêutica e usos dos referidos compostos |
US20070208053A1 (en) * | 2006-01-19 | 2007-09-06 | Arnold Lee D | Fused heterobicyclic kinase inhibitors |
BRPI0709866B8 (pt) | 2006-04-03 | 2021-05-25 | Astellas Pharma Inc | compostos héteros e composição farmacêutica compreendendo ditos compostos |
RU2448708C3 (ru) | 2006-05-18 | 2017-09-28 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Противоопухолевое средство против рака щитовидной железы |
CN101448827A (zh) * | 2006-05-22 | 2009-06-03 | 阿斯利康(瑞典)有限公司 | 吲哚衍生物 |
EA015700B1 (ru) * | 2006-07-06 | 2011-10-31 | Солвей Фармасьютикалс Б.В. | Азаиндольные производные с сочетанием частичного агонизма к никотиновому ацетилхолиновому рецептору и ингибирования обратного захвата дофамина |
US7964728B2 (en) * | 2006-07-06 | 2011-06-21 | Solvay Pharmaceuticals B.V. | Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition |
GB0617161D0 (en) * | 2006-08-31 | 2006-10-11 | Vernalis R&D Ltd | Enzyme inhibitors |
PT2526933E (pt) | 2006-09-22 | 2015-06-23 | Pharmacyclics Inc | Inibidores da tirosina-quinase de bruton |
WO2008063888A2 (fr) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Composés modulant l'activité de c-fms et/ou de c-kit et utilisations associées |
WO2008079909A1 (fr) * | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Composés et méthodes de modulation des kinases, et indications connexes |
PE20121126A1 (es) * | 2006-12-21 | 2012-08-24 | Plexxikon Inc | Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa |
AU2007336811A1 (en) * | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
EP2815750A1 (fr) | 2006-12-21 | 2014-12-24 | Vertex Pharmaceuticals Incorporated | Dérivés de 5-cyano-4-(pyrrolo [2,3b] pyridine-3-yl)-pyrimidine utiles en tant qu'inhibiteurs de kinase de protéine |
US20120101113A1 (en) | 2007-03-28 | 2012-04-26 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
IL295053A (en) * | 2007-03-28 | 2022-09-01 | Pharmacyclics Llc | Broton tyrosine kinase inhibitors |
ES2529790T3 (es) | 2007-04-13 | 2015-02-25 | Dana-Farber Cancer Institute, Inc. | Métodos de tratamiento de cáncer resistente a agentes terapéuticos de ERBB |
GB0710528D0 (en) * | 2007-06-01 | 2007-07-11 | Glaxo Group Ltd | Novel compounds |
US20080312259A1 (en) | 2007-06-13 | 2008-12-18 | Incyte Corporation | SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE |
BRPI0814423B1 (pt) * | 2007-07-17 | 2022-04-19 | Plexxikon, Inc | Compostos que modulam quinase e composição farmacêutica compreendendo os mesmos |
MX2010001636A (es) * | 2007-08-14 | 2010-03-15 | Hoffmann La Roche | Derivados de pirazolo[3,4-d]-pirimidina como agentes antiproliferativos. |
JP5558353B2 (ja) | 2007-08-17 | 2014-07-23 | ユニバーシティー オブ メリーランド,ボルティモア | Lcksh2ドメイン結合の小分子阻害剤 |
CA2639416C (fr) | 2007-09-11 | 2019-12-31 | F. Hoffmann-La Roche Ag | Test de diagnostic pour la susceptibilite aux inhibiteurs de la b-raf kinase |
DE102007045919B4 (de) | 2007-09-26 | 2018-07-05 | Bayer Intellectual Property Gmbh | Wirkstoffkombinationen mit insektiziden und akariziden Eigenschaften |
DE102007045956A1 (de) | 2007-09-26 | 2009-04-09 | Bayer Cropscience Ag | Wirkstoffkombination mit insektiziden und akariziden Eigenschaften |
AU2008317406B2 (en) | 2007-10-25 | 2013-07-18 | Merck Sharp & Dohme Corp. | Therapeutic compounds |
EP2242755B1 (fr) | 2008-01-08 | 2012-09-12 | Array Biopharma, Inc. | Pyrrolopyridines en tant qu'inhibiteurs de kinase |
US8426396B2 (en) * | 2008-01-08 | 2013-04-23 | Shriners Hospitals For Children | Treatment for achondroplasia |
CN101965347B (zh) | 2008-01-09 | 2013-01-02 | 阵列生物制药公司 | 作为激酶抑制剂的吡唑并吡啶 |
AU2009206775A1 (en) * | 2008-01-22 | 2009-07-30 | Merck Patent Gmbh | Protein kinase inhibitors and use thereof |
CN101945877B (zh) * | 2008-02-25 | 2013-07-03 | 霍夫曼-拉罗奇有限公司 | 吡咯并吡嗪激酶抑制剂 |
CL2009000447A1 (es) | 2008-02-29 | 2010-01-04 | Array Biopharma Inc Y Genentech Inc | Compuestos derivados de (1h-pirrolo{2,3-b}piridin-5-il)-sulfonamido-benzamida sustituida; procedimiento de preparacion; composicion farmaceutica; y su uso en el tratamiento del cancer, a travez de la inhibicion de raf. |
WO2009111280A1 (fr) | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | Dérivés de n-(6-aminopyridin-3-yl)-3-(sulfonamido) benzamide comme inhibiteurs de b-raf pour le traitement du cancer |
AU2009222144A1 (en) | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | Pyrazole [3, 4-b] pyridine Raf inhibitors |
UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
US8158636B2 (en) | 2008-05-19 | 2012-04-17 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
PE20091846A1 (es) | 2008-05-19 | 2009-12-16 | Plexxikon Inc | DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS |
CN102036982A (zh) * | 2008-05-21 | 2011-04-27 | 巴斯夫欧洲公司 | 作为杀真菌剂的取代吡啶-4-基甲基磺酰胺 |
JP2011521924A (ja) * | 2008-05-28 | 2011-07-28 | ビーエーエスエフ ソシエタス・ヨーロピア | 殺菌剤としての置換ピリジン−4−イル−メチルスルホンアミド |
JP5767965B2 (ja) * | 2008-06-10 | 2015-08-26 | プレキシコン インコーポレーテッドPlexxikon Inc. | キナーゼを調節する5h−ピロロ[2,3−b]ピラジン誘導体、およびその適応症 |
WO2009152087A1 (fr) | 2008-06-10 | 2009-12-17 | Plexxikon, Inc. | Composés hétéroaryles bicycliques et procédés destinés à la modulation de kinases, et des indications pour celle-ci |
AR072008A1 (es) * | 2008-06-13 | 2010-07-28 | Merck & Co Inc | Compuestos heterobiciclicos como agentes de inhibicion de quinasa p38 |
US9447049B2 (en) | 2010-03-01 | 2016-09-20 | University Of Tennessee Research Foundation | Compounds for treatment of cancer |
WO2009157196A1 (fr) | 2008-06-25 | 2009-12-30 | 武田薬品工業株式会社 | Composé amide |
AU2009270856B2 (en) | 2008-07-16 | 2013-07-25 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors |
DE102008052943A1 (de) | 2008-10-23 | 2010-04-29 | Merck Patent Gmbh | Azaindolderivate |
US8592448B2 (en) | 2008-11-20 | 2013-11-26 | OSI Pharmaceuticals, LLC | Substituted pyrrolo[2,3-b]-pyridines and -pyrazines |
AU2009324894B2 (en) * | 2008-11-25 | 2015-04-09 | University Of Rochester | MLK inhibitors and methods of use |
US8318446B2 (en) * | 2008-12-05 | 2012-11-27 | California Institute Of Technology | DNA-damage-induced proteolysis |
US8017555B2 (en) * | 2009-02-10 | 2011-09-13 | Divergence, Inc. | Compositions and methods for controlling nematodes |
CN102421776A (zh) * | 2009-03-11 | 2012-04-18 | 普莱希科公司 | 抑制Raf激酶的吡咯并[2,3-b]吡啶衍生物 |
EP2406260A1 (fr) * | 2009-03-11 | 2012-01-18 | Plexxikon, Inc. | Derives de pyrrolo [2, 3-b]pyridine pour l'inhibition de raf kinases |
WO2010111527A1 (fr) * | 2009-03-26 | 2010-09-30 | Plexxikon, Inc. | Pyrazolo [ 3, 4 -b] pyridines en tant qu'inhibiteurs de la kinase et leur utilisation médicale |
AR078033A1 (es) * | 2009-04-03 | 2011-10-12 | Plexxikon Inc | Una dispersion solida, que contiene al compuesto {3-[5-(4-(cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico, composiciones y formulaciones que comprenden a dicha dispersion solida; metodos para fabricar dicha dispersion solida, formas 1 y 2 de |
TW201041888A (en) * | 2009-05-06 | 2010-12-01 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
ES2487542T3 (es) | 2009-05-22 | 2014-08-21 | Incyte Corporation | Derivados de N-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de cinasas Janus |
CN106967070A (zh) | 2009-05-22 | 2017-07-21 | 因塞特控股公司 | 作为jak抑制剂的化合物 |
US9034875B2 (en) | 2009-05-26 | 2015-05-19 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
DK2435432T6 (da) | 2009-05-26 | 2023-12-18 | Abbvie Ireland Unlimited Co | Apoptose-inducerende midler til behandling af cancer og immune og autoimmune sygdomme |
US20220315555A1 (en) | 2009-05-26 | 2022-10-06 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
GEP20156325B (en) | 2009-06-17 | 2015-07-10 | Vertex Pharma | Inhibitors of influenza viruses replication |
AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
US8329724B2 (en) | 2009-08-03 | 2012-12-11 | Hoffmann-La Roche Inc. | Process for the manufacture of pharmaceutically active compounds |
MX2012002317A (es) | 2009-08-24 | 2012-06-25 | Ascepion Pharmaceuticals Inc | Compuestos de urea que contienen heteroarilo 5,6-biciclicos como inhibidores de cinasa. |
US20120157451A1 (en) | 2009-08-28 | 2012-06-21 | Genentech, Inc | Raf inhibitor compounds and methods of use thereof |
JP2013503189A (ja) | 2009-08-28 | 2013-01-31 | アレイ バイオファーマ、インコーポレイテッド | Raf阻害化合物およびその使用方法 |
JP2013503187A (ja) | 2009-08-28 | 2013-01-31 | アレイ バイオファーマ、インコーポレイテッド | Raf阻害化合物およびその使用方法 |
JP2013503193A (ja) | 2009-08-28 | 2013-01-31 | ジェネンテック, インコーポレイテッド | Raf阻害剤化合物およびその使用方法 |
WO2011025968A1 (fr) | 2009-08-28 | 2011-03-03 | Array Biopharma Inc. | Composés 1h-pyrazolo[3,4-b]pyridines pour l'inhibition des raf kinases |
CN102712646A (zh) * | 2009-08-28 | 2012-10-03 | 阵列生物制药公司 | Raf抑制剂化合物及其使用方法 |
AR078012A1 (es) | 2009-09-01 | 2011-10-05 | Incyte Corp | Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus |
CA2778707A1 (fr) | 2009-10-23 | 2011-04-28 | Mannkind Corporation | Immunotherapie pour le cancer et procede de traitement du cancer |
ES2633317T3 (es) | 2009-11-06 | 2017-09-20 | Plexxikon, Inc. | Compuestos y métodos para la modulación de quinasas, e indicaciones para ello |
WO2011060216A1 (fr) | 2009-11-12 | 2011-05-19 | Concert Pharmaceuticals Inc. | Azaindoles substitués |
SG10201407718WA (en) | 2009-11-18 | 2015-01-29 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
DE102009058280A1 (de) * | 2009-12-14 | 2011-06-16 | Merck Patent Gmbh | Thiazolderivate |
WO2011079133A2 (fr) | 2009-12-23 | 2011-06-30 | Plexxikon, Inc. | Composés et méthodes pour la modulation des kinases, et leurs indications |
US9180127B2 (en) | 2009-12-29 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
JP2013516479A (ja) | 2010-01-06 | 2013-05-13 | ジョゼフ・ピー・エリコ | 標的薬物を開発する方法および組成物 |
US8658170B2 (en) | 2010-01-06 | 2014-02-25 | Joseph P. Errico | Combination therapy with MDM2 and EFGR inhibitors |
US9163015B2 (en) * | 2010-02-11 | 2015-10-20 | Vanderbilt University | Pyrazolopyridine, pyrarolopyrazine, pyrazolopyrimidine, pyrazolothiophene and pyrazolothiazole compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
US11084811B2 (en) | 2010-03-01 | 2021-08-10 | Oncternal Therapeutics, Inc. | Compounds for treatment of cancer |
TWI766281B (zh) | 2010-03-10 | 2022-06-01 | 美商英塞特控股公司 | 作為jak1抑制劑之哌啶-4-基三亞甲亞胺衍生物 |
WO2011119842A1 (fr) | 2010-03-25 | 2011-09-29 | The J. David Gladstone Institutes | Compositions et procédés pour traiter des troubles neurologiques |
DK2558446T5 (da) * | 2010-04-16 | 2019-12-09 | Ac Immune Sa | Nye forbindelser til behandling af sygdomme associerede med amyloid- eller amyloidlignende proteiner |
TWI510487B (zh) | 2010-04-21 | 2015-12-01 | Plexxikon Inc | 用於激酶調節的化合物和方法及其適應症 |
CN102917707A (zh) * | 2010-05-06 | 2013-02-06 | 默沙东公司 | 可用作faah调节剂的氮杂吲哚衍生物 |
US20130072495A1 (en) | 2010-05-14 | 2013-03-21 | OSI Pharmaceuticals, LLC | Fused bicyclic kinase inhibitors |
AR081039A1 (es) * | 2010-05-14 | 2012-05-30 | Osi Pharmaceuticals Llc | Inhibidores biciclicos fusionados de quinasa |
KR102132405B1 (ko) | 2010-05-20 | 2020-07-09 | 어레이 바이오파마 인크. | Trk 키나제 저해제로서의 매크로시클릭 화합물 |
PE20130216A1 (es) | 2010-05-21 | 2013-02-27 | Incyte Corp | Formulacion topica para un inhibidor de jak |
EP2576566B1 (fr) * | 2010-05-28 | 2015-10-28 | Merck Sharp & Dohme B.V. | Composés thiéno(2,3b)pyrazine en tant qu'inhibiteurs de b-raf |
EA201890869A3 (ru) | 2010-06-03 | 2019-03-29 | Фармасайкликс, Инк. | Применение ингибиторов тирозинкиназы брутона (btk) |
EP2580336B1 (fr) | 2010-06-09 | 2017-05-10 | Bayer CropScience NV | Procédés et moyens pour modifier un génome végétal au niveau d'une séquence nucléotidique habituellement utilisée dans l'ingénierie des génomes végétaux |
US8779150B2 (en) | 2010-07-21 | 2014-07-15 | Hoffmann-La Roche Inc. | Processes for the manufacture of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1 H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide |
EP2598660B1 (fr) | 2010-07-26 | 2017-03-15 | Biomatrica, INC. | Compositions de stabilisation d'adn, d'arn, de protéines dans le sang et d'autres échantillons biologiques lors du transport et du stockage à températures ambiantes |
EP2598661B1 (fr) | 2010-07-26 | 2017-09-27 | Biomatrica, INC. | Compositions de stabilisation d'adn, d'arn, de protéines salivaires et d'autres échantillons biologiques lors du transport et du stockage à températures ambiantes |
US20120045433A1 (en) | 2010-08-17 | 2012-02-23 | Kapil Dhingra | Combination therapy |
US8709419B2 (en) | 2010-08-17 | 2014-04-29 | Hoffmann-La Roche, Inc. | Combination therapy |
US20120208837A1 (en) | 2010-09-13 | 2012-08-16 | Roger Tung | Substituted azaindoles |
UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
CA2811805A1 (fr) | 2010-10-29 | 2012-05-03 | Abbvie Inc. | Dispersions solides contenant un agent induisant l'apoptose |
KR101236731B1 (ko) | 2010-11-02 | 2013-02-25 | 한국과학기술원 | 아자인돌 화합물, 이를 포함하는 pi3k 저해제용 약학 조성물 및 pi3k와 연관된 질환 치료용 약학 조성물 |
AR083933A1 (es) | 2010-11-19 | 2013-04-10 | Incyte Corp | Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak |
JP5917544B2 (ja) | 2010-11-19 | 2016-05-18 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Jak阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン |
KR101923364B1 (ko) | 2010-11-23 | 2018-11-30 | 애브비 인코포레이티드 | 아폽토시스유도제의 염 및 결정형 |
DK2642999T3 (en) | 2010-11-23 | 2017-01-09 | Abbvie Ireland Unlimited Co | METHODS OF TREATMENT FOR USING selectivity-VE BCL-2 INHIBITORS |
US9296811B2 (en) | 2010-12-02 | 2016-03-29 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods for treating a tumor using an antibody that specifically binds HMW-MAA |
US9295669B2 (en) | 2010-12-14 | 2016-03-29 | Hoffman La-Roche Inc. | Combination therapy for proliferative disorders |
MX2013006836A (es) | 2010-12-16 | 2013-09-26 | Vertex Pharma | Inhibidores de la replicacion de los virus de la influenza. |
JP2014505052A (ja) | 2011-01-06 | 2014-02-27 | ベータ ファルマ カナダ インコーポレーテッド | 癌の治療および予防用の新規なウレア |
MA34948B1 (fr) * | 2011-02-07 | 2014-03-01 | Plexxikon Inc | Composes et procedes de modulation de kinase, et leurs indications |
EP2672963A4 (fr) | 2011-02-08 | 2015-06-24 | Childrens Medical Center | Méthodes de traitement d'un mélanome |
US9993480B2 (en) | 2011-02-18 | 2018-06-12 | Novartis Pharma Ag | mTOR/JAK inhibitor combination therapy |
TWI558702B (zh) * | 2011-02-21 | 2016-11-21 | 普雷辛肯公司 | 醫藥活性物質的固態形式 |
US20140199292A1 (en) * | 2011-03-15 | 2014-07-17 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Compositions and methods for inhibiting tumor development caused by chemotherapy induced senescence |
CN103857395A (zh) | 2011-04-01 | 2014-06-11 | 基因泰克公司 | Akt抑制剂化合物和阿比特龙的组合及使用方法 |
WO2012138809A1 (fr) * | 2011-04-05 | 2012-10-11 | Dawei Zhang | Utilisation de composés hétérocycliques en tant qu'inhibiteurs des kinases |
CA2828946C (fr) | 2011-04-18 | 2016-06-21 | Eisai R&D Management Co., Ltd. | Agent therapeutique pour les tumeurs |
AU2012253525B2 (en) * | 2011-05-10 | 2016-09-22 | Brunangelo Falini | Hairy cell leukemia biomarkers and methods of using same |
JP2014513724A (ja) | 2011-05-16 | 2014-06-05 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 融合二環キナーゼ阻害剤 |
RU2631487C2 (ru) | 2011-05-17 | 2017-09-22 | Плексксикон Инк. | Модуляция киназ и показания к её применению |
EP2714688B1 (fr) | 2011-05-26 | 2016-02-24 | Daiichi Sankyo Company, Limited | Composés hétérocycliques comme inhibiteurs de proteines kinases |
ES2841809T3 (es) | 2011-06-03 | 2021-07-09 | Eisai R&D Man Co Ltd | Biomarcadores para pronosticar y evaluar el grado de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib |
US8877742B2 (en) | 2011-06-10 | 2014-11-04 | Glaxosmithkline Intellectual Property Limited | Compounds |
EA201490042A1 (ru) | 2011-06-20 | 2014-10-30 | Инсайт Корпорейшн | Азетидинил-фенил-, пиридил- или пиразинилкарбоксамидные производные как ингибиторы jak |
WO2013010136A2 (fr) | 2011-07-13 | 2013-01-17 | Pharmacyclics, Inc. | Inhibiteurs de tyrosine kinase de bruton |
TW201840336A (zh) | 2011-08-01 | 2018-11-16 | 美商建南德克公司 | 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法 |
UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
WO2013023119A1 (fr) | 2011-08-10 | 2013-02-14 | Novartis Pharma Ag | Polythérapie par jak p13k/mtor |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
WO2013029043A1 (fr) * | 2011-08-25 | 2013-02-28 | Reaction Biology Corp. | Inhibiteurs sélectifs de kinase |
CN104053442B (zh) | 2011-08-26 | 2017-06-23 | 润新生物公司 | 某些化学实体、组合物及方法 |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
JP6093768B2 (ja) * | 2011-09-14 | 2017-03-08 | ニューファーマ, インコーポレイテッド | 特定の化学的実体、組成物、および方法 |
EP2570127A1 (fr) | 2011-09-16 | 2013-03-20 | Sanofi | Compositions et procédés pour traiter le cancer avec un inhibiteur bêta PI3KB et un inhibiteur de la voie MAPK, incluant des inhibiteurs MEK et RAF |
CN103930111A (zh) | 2011-09-19 | 2014-07-16 | 霍夫曼-拉罗奇有限公司 | 包含c-met拮抗剂和b-raf拮抗剂的组合治疗 |
EP2771011A4 (fr) * | 2011-10-24 | 2015-04-15 | Glaxosmithkline Ip No 2 Ltd | Composés chimiques |
AU2012340200B2 (en) | 2011-11-17 | 2017-10-12 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-Jun-N-Terminal Kinase (JNK) |
US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
SI2797888T1 (sl) | 2011-12-31 | 2017-01-31 | BeiGene, Ltd. Mourant Ozannes Corporate Services (Cayman) Limited | Zlite triciklične spojine kot inhibitorji kinaze raf |
WO2013109142A1 (fr) | 2012-01-16 | 2013-07-25 | Stichting Het Nederlands Kanker Instituut | Inhibition de la voie des mapk/erk et pdk combinée dans des cas de néoplasie |
CN102603734A (zh) * | 2012-01-19 | 2012-07-25 | 盛世泰科生物医药技术(苏州)有限公司 | 一种蛋白激酶抑制剂及其应用 |
WO2013112950A2 (fr) | 2012-01-25 | 2013-08-01 | Neupharma, Inc. | Entités chimiques particulières, compositions et procédés |
US9216170B2 (en) | 2012-03-19 | 2015-12-22 | Hoffmann-La Roche Inc. | Combination therapy for proliferative disorders |
US9358235B2 (en) | 2012-03-19 | 2016-06-07 | Plexxikon Inc. | Kinase modulation, and indications therefor |
US9527852B2 (en) | 2012-03-28 | 2016-12-27 | Neuropore Therapies, Inc. | Phenyl-urea and phenyl-carbamate derivatives as inhibitors of protein aggregation |
MY168958A (en) * | 2012-04-23 | 2019-01-28 | Genentech Inc | Intermediates and processes for preparing compounds |
AR091079A1 (es) | 2012-05-18 | 2014-12-30 | Incyte Corp | Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak |
EP2858501A4 (fr) * | 2012-05-22 | 2015-12-09 | Merck Sharp & Dohme | Inhibiteurs de kinase trk-a, compositions et méthodes correspondantes |
US10077474B2 (en) * | 2012-05-29 | 2018-09-18 | Abbott Molecular, Inc. | Method of designing primers, method of detecting single nucleotide polymorphisms (SNPs), method of distinguishing SNPs, and related primers, detectable oligonucleotides, and kits |
US9150570B2 (en) * | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
EP2855459B1 (fr) | 2012-05-31 | 2020-04-29 | F.Hoffmann-La Roche Ag | Dérives d'aminoquinazoline et de pyridopyrimidine |
CA3015208C (fr) | 2012-06-04 | 2024-01-02 | Pharmacyclics Llc | Formes cristallines d'un inhibiteur de tyrosine kinase de bruton |
JP2015522037A (ja) | 2012-07-03 | 2015-08-03 | ラシオファルム ゲーエムベーハー | ベムラフェニブコリン塩の固体形態 |
CN104704129A (zh) | 2012-07-24 | 2015-06-10 | 药品循环公司 | 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变 |
WO2014024077A1 (fr) * | 2012-08-07 | 2014-02-13 | Aurigene Discovery Technologies Limited | Dérivés de 5-(1h-pyrazol-4-yl)-1h-pyrrolo[2,3-b]pyridine utilisés comme inhibiteurs de kinases |
BR112015003418A2 (pt) | 2012-08-17 | 2017-07-04 | Hoffmann La Roche | produto farmacêutico, conjunto, métodos para estender a duração da resposta ao tratamento, de retardar ou prevenir o desenvolvimento de resistência ao tratamento, para a seleção de uma terapia e para otimizar a eficácia terapêutica. |
CN103626765B (zh) * | 2012-08-27 | 2016-08-10 | 广东东阳光药业有限公司 | 取代的氮杂吲哚化合物及其盐、组合物和用途 |
TWI601725B (zh) | 2012-08-27 | 2017-10-11 | 加拓科學公司 | 取代的氮雜吲哚化合物及其鹽、組合物和用途 |
AU2013312477B2 (en) | 2012-09-06 | 2018-05-31 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2014047648A1 (fr) | 2012-09-24 | 2014-03-27 | Neupharma, Inc. | Entités chimiques particulières, compositions et procédés |
CN103613591B (zh) * | 2012-09-29 | 2016-04-13 | 上海科州药物研发有限公司 | 作为cMet抑制剂的化合物及其制备方法和用途 |
US9163021B2 (en) | 2012-10-04 | 2015-10-20 | Pfizer Limited | Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors |
EA028605B1 (ru) * | 2012-10-08 | 2017-12-29 | Атрива Терапьютикс Гмбх | Комбинация озельтамивира и ингибитора mek для лечения вирусных заболеваний |
WO2014063068A1 (fr) | 2012-10-18 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs de cycline-dépendante kinase 7 (cdk7) |
WO2014063054A1 (fr) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs de kinase moelle osseuse sur chromosome x (bmx) et leurs utilisations |
WO2014063061A1 (fr) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Petites molécules marquées de façon hydrophobe en tant qu'inducteurs de la dégradation de protéine |
EP2916838B1 (fr) | 2012-11-12 | 2019-03-13 | Neupharma, Inc. | Certaines entités chimiques, compositions et certains procédés |
BR112015011171A2 (pt) | 2012-11-15 | 2017-07-11 | Pharmacyclics Inc | compostos de pirrolopirimidina como inibidores da quinase |
SG11201503695XA (en) | 2012-11-15 | 2015-06-29 | Incyte Corp | Sustained-release dosage forms of ruxolitinib |
US9260426B2 (en) * | 2012-12-14 | 2016-02-16 | Arrien Pharmaceuticals Llc | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors |
US9725703B2 (en) | 2012-12-20 | 2017-08-08 | Biomatrica, Inc. | Formulations and methods for stabilizing PCR reagents |
MX2015004979A (es) | 2012-12-21 | 2015-07-17 | Eisai R&D Man Co Ltd | Forma amorfa de derivado de quinolina y metodo para su produccion. |
HUE036739T2 (hu) | 2012-12-21 | 2018-07-30 | Plexxikon Inc | Vegyületek és eljárások kináz modulációra, és azok indikációi |
JP6437452B2 (ja) | 2013-01-14 | 2018-12-12 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Pimキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物 |
NZ710079A (en) | 2013-01-15 | 2020-01-31 | Incyte Holdings Corp | Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors |
WO2014130856A2 (fr) * | 2013-02-21 | 2014-08-28 | Wayne Rothbaum | Traitement de troubles associés au squelette |
KR20150118159A (ko) | 2013-02-22 | 2015-10-21 | 에프. 호프만-라 로슈 아게 | 암의 치료 방법 및 약물 내성의 예방 방법 |
CN109568312A (zh) * | 2013-03-05 | 2019-04-05 | 田纳西大学研究基金会 | 用于治疗癌症的化合物 |
HUE057262T2 (hu) | 2013-03-06 | 2022-04-28 | Incyte Holdings Corp | Eljárás és köztitermékek JAK inhibitor elõállítására |
US20140275082A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
CA2900951A1 (fr) | 2013-03-14 | 2014-10-02 | Ratiopharm Gmbh | Formes solides de chlorhydrate de vemurafenib |
PL2970265T3 (pl) | 2013-03-15 | 2018-11-30 | Plexxikon Inc. | Heterocykliczne związki i ich zastosowania |
CA2904770A1 (fr) | 2013-03-15 | 2014-09-18 | Sanofi | Composition antitumorale comprenant un inhibiteur de pi3kbeta et un inhibiteur de raf, pour surmonter la resistance de cellules cancereuses |
JP2016520528A (ja) | 2013-03-15 | 2016-07-14 | ジェネンテック, インコーポレイテッド | 癌の治療及び抗癌剤耐性の防止方法 |
US20140303121A1 (en) | 2013-03-15 | 2014-10-09 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
US9206188B2 (en) | 2013-04-18 | 2015-12-08 | Arrien Pharmaceuticals Llc | Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors |
AU2014266223B2 (en) | 2013-05-14 | 2020-06-25 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
SG11201509338QA (en) | 2013-05-30 | 2015-12-30 | Plexxikon Inc | Compounds for kinase modulation, and indications therefor |
WO2015002729A2 (fr) | 2013-06-13 | 2015-01-08 | Biomatrica, Inc. | Stabilisation de cellules |
JP6380862B2 (ja) | 2013-06-28 | 2018-08-29 | ベイジーン リミテッド | 複数種類のキナーゼの阻害剤としての縮合三環式アミド系化合物 |
TWI680760B (zh) * | 2013-07-12 | 2020-01-01 | 印度商皮拉馬爾企業有限公司 | 治療黑色素瘤的藥物組合 |
US9421208B2 (en) | 2013-08-02 | 2016-08-23 | Pharmacyclics Llc | Methods for the treatment of solid tumors |
US9655854B2 (en) | 2013-08-07 | 2017-05-23 | Incyte Corporation | Sustained release dosage forms for a JAK1 inhibitor |
ES2709509T3 (es) | 2013-08-12 | 2019-04-16 | Pharmacyclics Llc | Procedimientos para el tratamiento de cáncer amplificado por HER2 |
AR097431A1 (es) | 2013-08-23 | 2016-03-16 | Incyte Corp | Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de quinasas pim |
WO2015041534A1 (fr) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | P90rsk en combinaison avec raf/erk/mek |
EP3046557A1 (fr) | 2013-09-20 | 2016-07-27 | Stichting Het Nederlands Kanker Instituut | Association de rock et de la voie mapk |
CA2925124A1 (fr) | 2013-09-30 | 2015-04-02 | Pharmacyclics Llc | Inhibiteurs de la tyrosine kinase de bruton |
ES2676734T3 (es) | 2013-10-18 | 2018-07-24 | Syros Pharmaceuticals, Inc. | Compuestos heteroatómicos útiles para el tratamiento de enfermedades proliferativas |
JP6491202B2 (ja) | 2013-10-18 | 2019-03-27 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | サイクリン依存性キナーゼ7(cdk7)の多環阻害剤 |
EP3421468B1 (fr) | 2013-11-13 | 2020-11-04 | Vertex Pharmaceuticals Incorporated | Procédés de préparation d'inhibiteurs de réplication de virus de la grippe |
RS59144B1 (sr) | 2013-11-13 | 2019-09-30 | Vertex Pharma | Inhibitori replikacije virusa influence |
US9856214B2 (en) * | 2013-11-15 | 2018-01-02 | The Wistar Institute Of Anatomy And Biology | EBNA1 inhibitors and their method of use |
WO2015075749A1 (fr) * | 2013-11-22 | 2015-05-28 | Laurus Labs Private Limited | Nouveaux procédés de préparation de vemurafenib |
CZ2013943A3 (cs) | 2013-11-27 | 2015-06-03 | Zentiva, K.S. | Krystalické formy vemurafenibu |
CN104710417B (zh) * | 2013-12-11 | 2020-09-08 | 上海科州药物研发有限公司 | 氮杂吲哚类衍生物及其合成方法 |
CA3168002A1 (fr) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Traitement du cancer faisant appel a des associations d'inhibiteurs de l'erk et de la raf |
CN104739823A (zh) * | 2013-12-28 | 2015-07-01 | 复旦大学附属华山医院 | 淫羊藿素在制备维罗非尼增敏剂中的用途 |
EP3094736A4 (fr) | 2014-01-14 | 2017-10-25 | Dana-Farber Cancer Institute, Inc. | Compositions et méthodes pour l'identification, l'évaluation, la prévention, et le traitement d'un mélanome à l'aide d'isoformes de pd-l1 |
WO2015134536A1 (fr) | 2014-03-04 | 2015-09-11 | Plexxikon Inc. | Composés et méthodes de modulation des kinases, et leurs indications |
WO2015143400A1 (fr) | 2014-03-20 | 2015-09-24 | Pharmacyclics, Inc. | Mutations de phospholipase c gamma 2 et associées aux résistances |
WO2015156674A2 (fr) | 2014-04-10 | 2015-10-15 | Stichting Het Nederlands Kanker Instituut | Méthode de traitement du cancer |
WO2015164614A1 (fr) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs de janus kinase et leurs utilisations |
WO2015164604A1 (fr) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs de janus kinase marqués de manière hydrophobe et utilisations associées |
CN106535900A (zh) * | 2014-05-06 | 2017-03-22 | 加利福尼亚大学董事会 | 使用braf抑制剂的伤口愈合 |
WO2015178770A1 (fr) | 2014-05-19 | 2015-11-26 | Stichting Het Nederlands Kanker Instituut | Compositions pour le traitement du cancer |
WO2015181628A1 (fr) * | 2014-05-27 | 2015-12-03 | Eisai R&D Management Co., Ltd. | Traitement de la leucémie myéloïde aiguë avec un inhibiteur de hck |
US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
TW201613916A (en) | 2014-06-03 | 2016-04-16 | Gilead Sciences Inc | TANK-binding kinase inhibitor compounds |
WO2015191632A1 (fr) | 2014-06-10 | 2015-12-17 | Biomatrica, Inc. | Stabilisation de thrombocytes à des températures ambiantes |
JP2017517558A (ja) * | 2014-06-13 | 2017-06-29 | ジェネンテック, インコーポレイテッド | 癌薬剤耐性の治療方法及び防止方法 |
US20230190750A1 (en) | 2014-06-13 | 2023-06-22 | Genentech, Inc. | Methods of treating and preventing cancer drug resistance |
TW201613919A (en) | 2014-07-02 | 2016-04-16 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase |
WO2016000615A1 (fr) * | 2014-07-02 | 2016-01-07 | Sunshine Lake Pharma Co., Ltd. | Composés hétéroaryles et leurs applications pharmaceutiques |
US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
CN106573060A (zh) | 2014-07-15 | 2017-04-19 | 豪夫迈·罗氏有限公司 | 使用pd‑1轴结合拮抗剂和mek抑制剂治疗癌症的组合物 |
AU2015296215A1 (en) | 2014-08-01 | 2017-03-23 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
US9545407B2 (en) | 2014-08-07 | 2017-01-17 | Pharmacyclics Llc | Formulations of a bruton's tyrosine kinase inhibitor |
ES2926687T3 (es) | 2014-08-28 | 2022-10-27 | Eisai R&D Man Co Ltd | Derivado de quinolina muy puro y método para su producción |
AU2015318233B2 (en) | 2014-09-15 | 2020-03-12 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
ES2881195T3 (es) | 2014-09-26 | 2021-11-29 | Gilead Sciences Inc | Derivados de aminotriazina útiles como compuestos inhibidores de quinasas que se unen a TANK |
EP3204516B1 (fr) | 2014-10-06 | 2023-04-26 | Dana-Farber Cancer Institute, Inc. | Biomarqueurs à base d'angiopoïétine -2 utilisés pour la prédiction de la réponse de point de contrôle anti-immunitaire |
WO2016073771A2 (fr) * | 2014-11-06 | 2016-05-12 | Ohio State Innovation Foundation | Dérivés de pyrrolopyrimidine utilisés en tant qu'inhibiteurs de la kinase mps1/ttk |
WO2016083956A1 (fr) * | 2014-11-29 | 2016-06-02 | Shilpa Medicare Limited | Vemurafenib sensiblement pur et ses sels |
EP3256470B1 (fr) * | 2014-12-23 | 2023-07-26 | Dana-Farber Cancer Institute, Inc. | Procédés pour induire la dégradation ciblée de protéines par des molécules bifonctionnelles |
US9694084B2 (en) | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
EP3236959A4 (fr) | 2014-12-23 | 2018-04-25 | Dana Farber Cancer Institute, Inc. | Inhibiteurs de la kinase cycline-dépendante 7 (cdk7) |
HUE064614T2 (hu) | 2015-02-25 | 2024-04-28 | Eisai R&D Man Co Ltd | Eljárás egy kinolin-származék keserû ízének elnyomására |
KR20170122220A (ko) | 2015-03-03 | 2017-11-03 | 파마싸이클릭스 엘엘씨 | 브루톤 타이로신 키나제 저해제의 약제학적 제제 |
KR102662228B1 (ko) | 2015-03-04 | 2024-05-02 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
CA2978518C (fr) | 2015-03-27 | 2023-11-21 | Nathanael S. Gray | Inhibiteurs de kinases cycline-dependantes |
WO2016164641A1 (fr) | 2015-04-08 | 2016-10-13 | Plexxikon Inc. | Composés et méthodes de modulation des kinases, et leurs indications |
CZ2015250A3 (cs) | 2015-04-14 | 2016-10-26 | Zentiva, K.S. | Amorfní formy vemurafenibu |
ES2774178T3 (es) | 2015-05-06 | 2020-07-17 | Plexxikon Inc | Síntesis de derivados de 1h-pirrolo[2,3-B] piridina que modulan cinasas |
KR102630889B1 (ko) | 2015-05-06 | 2024-01-30 | 다이이치 산쿄 인코포레이티드 | 키나제를 조절하는 화합물의 고형 형태 |
WO2016183116A1 (fr) | 2015-05-13 | 2016-11-17 | Vertex Pharmaceuticals Incorporated | Procédés de préparation d'inhibiteurs de réplication des virus de la grippe |
WO2016183120A1 (fr) | 2015-05-13 | 2016-11-17 | Vertex Pharmaceuticals Incorporated | Inhibiteurs de la réplication des virus de la grippe |
JP6771491B2 (ja) | 2015-05-14 | 2020-10-21 | ザ ウィスター インスティテュート オブ アナトミー アンド バイオロジー | Ebna1阻害剤およびその使用方法 |
US9814714B2 (en) | 2015-05-22 | 2017-11-14 | Plexxikon Inc. | Kinase modulation, and indications therefor |
US9776998B2 (en) | 2015-05-22 | 2017-10-03 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
WO2016196244A1 (fr) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Composés de pyridineamine utiles en tant qu'inhibiteurs de kinase pim |
LT3307734T (lt) * | 2015-06-09 | 2020-05-11 | Abbvie Inc. | Branduolinio receptoriaus moduliatoriai (ror), skirti uždegiminių ir autoimuninių ligų gydymui |
AU2016276963C1 (en) | 2015-06-12 | 2021-08-05 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
AU2016279474B2 (en) | 2015-06-16 | 2021-09-09 | Eisai R&D Management Co., Ltd. | Anticancer agent |
LT3322706T (lt) | 2015-07-16 | 2021-03-10 | Array Biopharma, Inc. | Pakeistieji pirazolo[1,5-a]piridino junginiai, kaip ret kinazės inhibitoriai |
CN107922396B (zh) * | 2015-07-20 | 2022-08-05 | 建新公司 | 集落刺激因子-1受体(csf-1r)抑制剂 |
WO2017019664A1 (fr) * | 2015-07-28 | 2017-02-02 | University Of Iowa Research Foundation | Compositions et méthodes de traitement du cancer |
WO2017019804A2 (fr) | 2015-07-28 | 2017-02-02 | Plexxikon Inc. | Composés et procédés de modulation des kinases, et indications associées |
CA2996978A1 (fr) | 2015-09-09 | 2017-03-16 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs de kinases cycline-dependantes |
TWI734699B (zh) | 2015-09-09 | 2021-08-01 | 美商英塞特公司 | Pim激酶抑制劑之鹽 |
US9771363B2 (en) | 2015-09-21 | 2017-09-26 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
US9920032B2 (en) | 2015-10-02 | 2018-03-20 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
WO2017066193A1 (fr) * | 2015-10-15 | 2017-04-20 | Princeton Drug Discovery, Llc | Nouveaux inhibiteurs de protéines kinases |
BR112018008357A2 (pt) | 2015-10-26 | 2018-11-27 | Array Biopharma Inc | mutações de ponto em câncer resistente a inibidor de trk e métodos relacionados às mesmas |
KR20180081591A (ko) | 2015-11-19 | 2018-07-16 | 제넨테크, 인크. | B-raf 억제제 및 면역 체크포인트 억제제를 사용하여 암을 치료하는 방법 |
SG11201804711RA (en) | 2015-12-07 | 2018-07-30 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
CN113588501A (zh) | 2015-12-08 | 2021-11-02 | 生物马特里卡公司 | 降低红细胞沉降速率 |
US10116776B2 (en) | 2015-12-14 | 2018-10-30 | Red.Com, Llc | Modular digital camera and cellular phone |
US10316049B2 (en) | 2015-12-17 | 2019-06-11 | Gilead Sciences, Inc. | Tank-binding kinase inhibitor compounds |
WO2017147316A1 (fr) * | 2016-02-25 | 2017-08-31 | Taxis Pharmaceuticals, Inc. | Procédés et intermédiaires de synthèse |
WO2017161045A1 (fr) | 2016-03-16 | 2017-09-21 | Plexxikon Inc. | Composés et procédés de modulation de kinases et indications associées |
AU2017246554B2 (en) | 2016-04-04 | 2022-08-18 | Loxo Oncology, Inc. | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
WO2017176744A1 (fr) | 2016-04-04 | 2017-10-12 | Loxo Oncology, Inc. | Méthodes de traitement de cancers pédiatriques |
AU2017249229A1 (en) | 2016-04-15 | 2018-10-04 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
HRP20230704T1 (hr) | 2016-05-18 | 2023-10-27 | Loxo Oncology, Inc. | Priprava (s)-n-(5-((r)-2-(2,5-difluorfenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroksipirolidin-1-karboksamida |
WO2017218544A1 (fr) * | 2016-06-13 | 2017-12-21 | Chemocentryx, Inc. | Méthodes de traitement du cancer du pancréas |
US11179484B2 (en) | 2016-06-24 | 2021-11-23 | University Of Iowa Research Foundation | Compositions and methods of treating melanoma |
RS60451B1 (sr) | 2016-07-01 | 2020-07-31 | Fermion Oy | Novi postupci za dobijanje vemurafeniba |
EP3484856B1 (fr) | 2016-07-12 | 2023-11-15 | Revolution Medicines, Inc. | 3-méthylpyrazines 2,5-disubstituées et 3-méthyl pyrazines 2,5,6-trisubstitués en tant qu'inhibiteurs allostériques de shp2 |
CN109715631B (zh) * | 2016-09-16 | 2022-02-18 | 德国亥姆霍兹慕尼黑中心健康与环境研究中心(有限公司) | Traf 6抑制剂 |
TW201815766A (zh) | 2016-09-22 | 2018-05-01 | 美商普雷辛肯公司 | 用於ido及tdo調節之化合物及方法以及其適應症 |
TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
EP3308773A1 (fr) | 2016-10-11 | 2018-04-18 | Recordati Industria Chimica E Farmaceutica SPA | Formulations de cystéamine et de dérivés de cystéamine |
EP3528798A4 (fr) | 2016-10-19 | 2020-10-21 | United States Government as Represented by The Department of Veterans Affairs | Compositions et méthodes pour le traitement du cancer |
JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
IL266751B (en) | 2016-11-23 | 2022-07-01 | Chemocentryx Inc | A method for the treatment of focal segmental tuberous sclerosis |
EP3554258B1 (fr) | 2016-12-15 | 2023-07-19 | Société des Produits Nestlé S.A. | Compositions et méthodes de modulation du phosphore ou des enzymes chez un animal de compagnie |
US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
EP3558991A2 (fr) | 2016-12-23 | 2019-10-30 | Plexxikon Inc. | Composés et procédés pour la modulation de cdk8, et indications associées |
BR112019012878A2 (pt) | 2016-12-23 | 2019-11-26 | Arvinas Operations Inc | compostos e métodos para a degradação alvo de polipeptídos de fibrossarcoma rapidamente acelerados |
US11040027B2 (en) | 2017-01-17 | 2021-06-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
WO2018136663A1 (fr) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Inhibiteurs de ret |
CA3049136C (fr) | 2017-01-18 | 2022-06-14 | Array Biopharma Inc. | Composes de pyrazolo[1,5-a]pyrazine substitues utilises en tant qu'inhibiteurs de la kinase ret |
EP3571199A1 (fr) | 2017-01-23 | 2019-11-27 | Revolution Medicines, Inc. | Composés bicycliques utilisés en tant qu'inhibiteurs allostériques de shp2 |
BR112019014527A2 (pt) | 2017-01-23 | 2020-02-27 | Revolution Medicines, Inc. | Compostos de piridina como inibidores de shp2 alostéricos |
JP7341060B2 (ja) | 2017-02-10 | 2023-09-08 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Mapk経路の活性化に関連付けられる癌の処置のための方法及び医薬組成物 |
JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
AU2018237047A1 (en) | 2017-03-20 | 2019-10-17 | Plexxikon Inc. | Crystalline forms of 4-(1-(1,1-di(pyridin-2-yl)ethyl)-6-(3,5-dimethylisoxazol-4-yl)-1H- pyrrolo[3,2-b]pyridin-3-yl)benzoic acid that inhibits bromodomain |
WO2018175324A1 (fr) | 2017-03-20 | 2018-09-27 | The Broad Institute, Inc. | Composés et méthodes de régulation de sécrétion d'insuline |
WO2018183762A1 (fr) * | 2017-03-29 | 2018-10-04 | United States Government As Represented By The Department Of Veterans Affairs | Méthodes et compositions pour le traitement du cancer |
CA3058183A1 (fr) | 2017-03-30 | 2018-10-04 | Taxis Pharmaceuticals, Inc. | Procedes de synthese et intermediaires de synthese |
CA3060147A1 (fr) * | 2017-04-28 | 2018-11-01 | Quartz Therapeutics, Inc. | Composes conjugues de degradation de raf |
WO2018210661A1 (fr) * | 2017-05-15 | 2018-11-22 | Basf Se | Composés hétéroaryle faisant office de fongicides agrochimiques |
US11161845B2 (en) * | 2017-05-19 | 2021-11-02 | Nflection Therapeutics, Inc. | Pyrrolopyridine-aniline compounds for treatment of dermal disorders |
MA49140A (fr) | 2017-05-19 | 2020-03-25 | Nflection Therapeutics Inc | Composés hétéroaromatiques-aniline fusionnés pour le traitement de troubles dermiques |
US10428067B2 (en) | 2017-06-07 | 2019-10-01 | Plexxikon Inc. | Compounds and methods for kinase modulation |
JP7221227B2 (ja) | 2017-06-30 | 2023-02-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 発毛を調節するための組成物及び方法 |
EP3658189A1 (fr) | 2017-07-25 | 2020-06-03 | Plexxikon Inc. | Formulation d'un composé modulant les kinases |
CN109384785B (zh) * | 2017-08-10 | 2021-09-28 | 浙江海正药业股份有限公司 | 吡咯并吡啶酮类衍生物、其制备方法及其在医药上的用途 |
AU2018329925A1 (en) | 2017-09-08 | 2020-03-05 | F. Hoffmann-La Roche Ag | Diagnostic and therapeutic methods for cancer |
TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
TW202410896A (zh) | 2017-10-10 | 2024-03-16 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
JP2020536919A (ja) | 2017-10-11 | 2020-12-17 | ケモセントリックス, インコーポレイテッド | Ccr2アンタゴニストによる巣状分節性糸球体硬化症の治療 |
AU2018347516A1 (en) | 2017-10-12 | 2020-05-07 | Revolution Medicines, Inc. | Pyridine, pyrazine, and triazine compounds as allosteric SHP2 inhibitors |
US10717735B2 (en) | 2017-10-13 | 2020-07-21 | Plexxikon Inc. | Solid forms of a compound for modulating kinases |
IL274027B2 (en) | 2017-10-26 | 2023-12-01 | Xynomic Pharmaceuticals Inc | B–RAF kinase inhibitor salt crystals |
BR112020007972A2 (pt) | 2017-10-27 | 2020-10-20 | Plexxikon, Inc. | formulações de composto que modula quinases |
AR113922A1 (es) | 2017-12-08 | 2020-07-01 | Incyte Corp | Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas |
MX2020006273A (es) | 2017-12-15 | 2020-09-14 | Revolution Medicines Inc | Compuestos policiclicos como inhibidores alostericos de shp2. |
WO2019133810A1 (fr) | 2017-12-28 | 2019-07-04 | Tract Pharmaceuticals, Inc. | Systèmes de culture de cellules souches pour cellules souches épithéliales colonnaires, et leurs utilisations |
US11524963B2 (en) | 2018-01-18 | 2022-12-13 | Array Biopharma Inc. | Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors |
JP7060694B2 (ja) | 2018-01-18 | 2022-04-26 | アレイ バイオファーマ インコーポレイテッド | Retキナーゼ阻害剤としての置換ピロロ[2,3-d]ピリミジン化合物 |
JP6997876B2 (ja) | 2018-01-18 | 2022-02-04 | アレイ バイオファーマ インコーポレイテッド | Retキナーゼ阻害剤としての置換ピラゾリル[4,3-c]ピリジン化合物 |
CN112105608B (zh) | 2018-01-30 | 2023-07-14 | 因赛特公司 | 制备(1-(3-氟-2-(三氟甲基)异烟碱基)哌啶-4-酮)的方法 |
CN111788195B (zh) | 2018-01-31 | 2023-11-21 | 海帕瑞吉尼克斯股份有限公司 | 用于促进肝脏再生或减少或预防肝细胞死亡的蛋白激酶mkk4抑制剂 |
EP3752200A1 (fr) | 2018-02-13 | 2020-12-23 | Vib Vzw | Ciblage d'une maladie résiduelle minimale dans le cancer avec des antagonistes de rxr |
JP2021518367A (ja) | 2018-03-20 | 2021-08-02 | プレキシコン インコーポレーテッドPlexxikon Inc. | Idoおよびtdo調節のための化合物および方法、ならびにそれらのための兆候 |
AU2019245420A1 (en) | 2018-03-30 | 2020-11-12 | Incyte Corporation | Treatment of hidradenitis suppurativa using JAK inhibitors |
WO2019195682A1 (fr) * | 2018-04-05 | 2019-10-10 | Beth Israel Deaconess Medical Center, Inc. | Modulateurs du récepteur d'hydrocarbure aryle et utilisations associées |
EP3560516A1 (fr) * | 2018-04-27 | 2019-10-30 | Bergen Teknologioverforing AS | Thérapie de combinaison comprenant du bêta-sitostérol en combinaison avec au moins un inhibiteur braf, un inhibiteur mek ou un inhibiteur erk et ses procédés et son utilisation |
EP3793546A4 (fr) | 2018-05-17 | 2021-12-08 | The Wistar Institute | Formes cristallines d'inhibiteur d'ebna1 et procédés de préparation et méthodes d'utilisation de celles-ci |
GB201808321D0 (en) * | 2018-05-21 | 2018-07-11 | Univ College Dublin Nat Univ Ireland Dublin | Compositions and uses thereof |
RU2687107C1 (ru) * | 2018-06-18 | 2019-05-07 | федеральное государственное автономное образовательное учреждение высшего образования "Московский физико-технический институт (государственный университет)" | Ингибитор braf киназы n-(3-(5-(4-хлорофенил)-1h-пиразоло[3,4-b]пиридин-3-карбонил)-2,4-дифторофенил) пропан-1-сульфонамид |
US11731968B2 (en) | 2018-06-21 | 2023-08-22 | Heparegenix Gmbh | Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
GB2612522B (en) * | 2018-07-06 | 2023-08-02 | The Regents Of The Univ Of Colorado A Body Corporate Existing Under The Laws Of The State Of Colorad | Genetically encoded system for constructing and detecting biologically active agents |
CA3104246A1 (fr) | 2018-07-16 | 2020-01-23 | Heparegenix Gmbh | Inhibiteurs de proteine kinase permettant de favoriser la regeneration du foie, ou de reduire ou de prevenir la mort des hepatocytes |
US20210253571A1 (en) * | 2018-07-19 | 2021-08-19 | Medshine Discovery Inc. | Azaindole derivative and use thereof as fgfr and c-met inhibitor |
AU2019314302A1 (en) | 2018-07-31 | 2021-01-28 | Loxo Oncology, Inc. | Spray-dried dispersions and formulations of (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoro propan-2-yl)-1H-pyrazole-4-carboxamide |
US11964988B2 (en) | 2018-09-10 | 2024-04-23 | Array Biopharma Inc. | Fused heterocyclic compounds as RET kinase inhibitors |
US20210244716A1 (en) | 2018-10-03 | 2021-08-12 | Jyväskylän Yliopisto | Vemurafenib and salts thereof for use in the treatment of enteroviral infections |
US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
CN112867803A (zh) | 2018-10-16 | 2021-05-28 | 诺华股份有限公司 | 单独的或与免疫标志物组合的肿瘤突变负荷作为生物标志物用于预测对靶向疗法的应答 |
SG11202104404XA (en) * | 2018-11-16 | 2021-05-28 | California Inst Of Techn | Erk inhibitors and uses thereof |
WO2020106306A1 (fr) | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Composés cyanoaryl-aniline pour le traitement d'affections de la peau |
JP2022510368A (ja) * | 2018-12-03 | 2022-01-26 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | タンキラーゼのインヒビターとしての4-ヘテロアリールカルボニル-n-(フェニルまたはヘテロアリール)ピペリジン-1-カルボキサミド |
US20220041579A1 (en) | 2018-12-19 | 2022-02-10 | Array Biopharma Inc. | Substituted quinoxaline compounds as inhibitors of fgfr tyrosine kinases |
CN113490666A (zh) | 2018-12-19 | 2021-10-08 | 奥瑞生物药品公司 | 作为fgfr酪氨酸激酶的抑制剂的取代的吡唑并[1,5-a]吡啶化合物 |
MX2021009426A (es) * | 2019-02-11 | 2021-09-10 | Merck Patent Gmbh | Derivados de indazolil-isoxazol para el tratamiento de enfermedades tales como cancer. |
US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
WO2020180959A1 (fr) | 2019-03-05 | 2020-09-10 | Incyte Corporation | Composés de pyrazolyl pyrimidinylamine en tant qu'inhibiteurs de cdk2 |
WO2020205560A1 (fr) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Composés sulfonylamides utilisés comme inhibiteurs de la cdk2 |
KR20220018475A (ko) | 2019-04-09 | 2022-02-15 | 플렉시콘 인코퍼레이티드 | Ep300 또는 cbp 조절 및 이의 표시를 위한 응축 아진 |
US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
WO2020223469A1 (fr) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Dérivés de n-(1-(méthylsulfonyl)pipéridin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine et composés apparentés utilisés en tant qu'inhibiteurs de kinase 2 dépendante des cyclines (cdk2) pour le traitement du cancer |
US20220227760A1 (en) * | 2019-05-29 | 2022-07-21 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
EP3976607A4 (fr) * | 2019-05-31 | 2023-07-19 | Fochon Biosciences, Ltd. | Dérivés de pyrrolo [2, 3-b] pyridine et de pyrazolo [3,4-b] pyridine substitués en tant qu'inhibiteurs de protéine kinase |
WO2021018820A1 (fr) | 2019-07-29 | 2021-02-04 | Heparegenix Gmbh | Inhibiteurs de protéine kinase de pyrazolo-pyridine substitués par hétéroaryle pour favoriser la régénération du foie ou réduire ou prévenir la mort des hépatocytes |
AR119765A1 (es) | 2019-08-14 | 2022-01-12 | Incyte Corp | Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2 |
US20220347182A1 (en) * | 2019-10-02 | 2022-11-03 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for the treatment of osteoarthritis |
MX2022004390A (es) | 2019-10-11 | 2022-08-08 | Incyte Corp | Aminas biciclicas como inhibidores de la cinasa dependiente de ciclina 2 (cdk2). |
CN111004210A (zh) * | 2019-10-23 | 2020-04-14 | 中山大学 | 化合物单晶及其制备方法 |
WO2021127443A1 (fr) | 2019-12-19 | 2021-06-24 | Arvinas Operations, Inc. | Composés et méthodes pour la dégradation ciblée du récepteur des androgènes |
AU2020413333A1 (en) | 2019-12-27 | 2022-06-16 | Schrödinger, Inc. | Cyclic compounds and methods of using same |
EP4087657A1 (fr) | 2020-01-08 | 2022-11-16 | Synthis Therapeutics, Inc. | Conjugués inhibiteurs d'alk5 et leurs utilisations |
EP4090659B1 (fr) | 2020-01-15 | 2024-06-12 | HepaRegeniX GmbH | Dérivés de 3-benzoyl-1h-pyrrolo[2,3-b]pyridine utilisés en tant qu'inhibiteurs de mkk4 pour le traitement de maladies du foie |
JP2023510220A (ja) * | 2020-01-17 | 2023-03-13 | テグ-キョンプク メディカル イノベーション ファウンデーション | 新規化合物、その調製方法、及びその使用 |
AU2021213317A1 (en) | 2020-01-28 | 2022-06-30 | Centre National De La Recherche Scientifique | Antisense oligonucleotide targeting LINC00518 for treating melanoma |
EP4135700A4 (fr) * | 2020-04-15 | 2024-04-17 | Pyramid Biosciences, Inc. | Procédés de préparation d'inhibiteurs de récepteurs à activité tyrosine kinase |
JP2023522949A (ja) | 2020-04-23 | 2023-06-01 | オプナ バイオ ソシエテ アノニム | Cd73調節のための化合物及び方法並びにそれらの表示 |
KR20210135092A (ko) * | 2020-05-04 | 2021-11-12 | 아주대학교산학협력단 | 톨-유사 수용체 7/9 억제 기능이 있는 길항성 소분자 화합물 |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
US11529335B2 (en) | 2020-07-31 | 2022-12-20 | University Of Iowa Research Foundation | Compositions and methods for treating cancer |
AU2021327375A1 (en) | 2020-08-21 | 2023-03-16 | Opna Bio SA | Combinational drug anticancer therapies |
US20230365584A1 (en) | 2020-09-10 | 2023-11-16 | Schrödinger, Inc. | Heterocyclic pericondensed cdc7 kinase inhibitors for the treatment of cancer |
WO2022063101A1 (fr) * | 2020-09-23 | 2022-03-31 | 劲方医药科技(上海)有限公司 | Composé tricyclique substitué par aroyle, son procédé de préparation et son utilisation |
CN114478528A (zh) * | 2020-10-28 | 2022-05-13 | 劲方医药科技(上海)有限公司 | 芳甲酰取代的三环化合物及其制法和用途 |
KR20230110286A (ko) * | 2020-11-17 | 2023-07-21 | 포천 바이오사이언시스, 리미티드 | 단백질 키나제 억제제로서 치환된 피롤로 [2,3-b] 피리딘 및 피라졸로 [3,4-b] 피리딘 유도체 |
EP4234558A1 (fr) * | 2020-12-07 | 2023-08-30 | Zhejiang Longcharm Bio-Tech Pharma. Co., Ltd. | Composé de pyrrolopyridine et son application |
EP4255420A1 (fr) * | 2020-12-07 | 2023-10-11 | Lieber Institute, Inc. | Composés d'inhibition de l'inositol hexakisphosphate kinase (ip6k) et leurs méthodes d'utilisation |
EP4267573A1 (fr) | 2020-12-23 | 2023-11-01 | Genzyme Corporation | Inhibiteurs deutérés du récepteur du facteur 1 de stimulation des colonies (csp-1r) |
EP4284804A1 (fr) | 2021-01-26 | 2023-12-06 | Schrödinger, Inc. | Composés tricycliques utiles dans le traitement du cancer, des troubles auto-immuns et des troubles inflammatoires |
CN112574200B (zh) * | 2021-02-26 | 2021-06-11 | 安润医药科技(苏州)有限公司 | Btk和/或btk的突变体c481s的小分子抑制剂 |
CN115073469B (zh) * | 2021-03-15 | 2023-12-22 | 药雅科技(上海)有限公司 | 吡咯并嘧啶类化合物作为激酶抑制剂的制备及其应用 |
JP2024511373A (ja) | 2021-03-18 | 2024-03-13 | ノバルティス アーゲー | がんのためのバイオマーカーおよびその使用 |
TW202300150A (zh) | 2021-03-18 | 2023-01-01 | 美商薛定諤公司 | 環狀化合物及其使用方法 |
TW202304890A (zh) * | 2021-04-14 | 2023-02-01 | 美商百歐克斯製藥公司 | Klk5雙環雜芳香族抑制劑 |
US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
WO2023059786A1 (fr) * | 2021-10-06 | 2023-04-13 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Inhibiteurs de ulk1 et procédés d'utilisation |
US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
CN116768896A (zh) * | 2022-03-15 | 2023-09-19 | 劲方医药科技(上海)有限公司 | Btk抑制剂的晶型及其酸式盐和其酸式盐的晶型 |
WO2023178240A2 (fr) * | 2022-03-16 | 2023-09-21 | The Children's Medical Center Corporation | Inhibition de pyk2 modulant une fonction de cellule immunitaire |
WO2024003350A1 (fr) | 2022-06-30 | 2024-01-04 | Universite De Strasbourg | Polythérapie pour mélanome |
CN115141197B (zh) * | 2022-07-27 | 2024-03-26 | 安徽医科大学 | 一种3-芳杂环取代苯基衍生物及其制备方法与用途 |
WO2024033381A1 (fr) | 2022-08-10 | 2024-02-15 | Vib Vzw | Inhibition de tcf4/itf2 dans le traitement du cancer |
US11957759B1 (en) | 2022-09-07 | 2024-04-16 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use |
WO2024111671A1 (fr) * | 2022-11-25 | 2024-05-30 | ゼノリス プライベート リミテッド | Aptamère d'acide nucléique |
Family Cites Families (166)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3124610A (en) * | 1964-03-10 | Preparation of intermediates | ||
US2234705A (en) * | 1940-04-12 | 1941-03-11 | Eastman Kodak Co | Cellulose organic derivative composition containing esters of monoalkoxy benzoic acids |
US2413258A (en) * | 1942-07-07 | 1946-12-24 | United Gas Improvement Co | Polystyrene-type resins plasticized with high boiling fatty acid alkyl esters |
US3067237A (en) * | 1959-04-14 | 1962-12-04 | Sterling Drug Inc | Lower-alkyl mono-or bis-(alkanesulfonamido) benzoate esters |
GB1141949A (en) | 1966-02-23 | 1969-02-05 | Sterling Drug Inc | 7-azaindole derivatives |
BR6794063D0 (pt) * | 1966-10-21 | 1973-09-18 | Minnesota Mining & Mfg | Processo para preparar perfluoral-quilsulfonamidas n-substituidas e composicoes herbicidas e fitoreguladoras nelas baseadas |
IL46853A0 (en) * | 1974-03-20 | 1975-05-22 | Bayer Ag | Novel alkoxycarbonylphenylureas,their preparation and their use as herbicides |
DE2413258A1 (de) * | 1974-03-20 | 1975-10-02 | Bayer Ag | Alkoxycarbonylphenylharnstoffe, verfahren zu ihrer herstellung und ihre verwendung als herbizide |
GB1573212A (en) * | 1976-04-15 | 1980-08-20 | Technicon Instr | Immunoassay for gentamicin |
US4301159A (en) * | 1980-06-20 | 1981-11-17 | Shionogi & Co., Ltd. | N-(Diethylaminoethyl)-2-alkoxy-benzamide derivatives |
AU547405B2 (en) * | 1981-07-08 | 1985-10-17 | Sanofi | Amidobenzamides |
US4664504A (en) * | 1983-01-20 | 1987-05-12 | Tokyo Shibaura Denki Kabushiki Kaisha | Image forming apparatus |
US4568649A (en) | 1983-02-22 | 1986-02-04 | Immunex Corporation | Immediate ligand detection assay |
US4626513A (en) * | 1983-11-10 | 1986-12-02 | Massachusetts General Hospital | Method and apparatus for ligand detection |
EP0142152B1 (fr) * | 1983-11-14 | 1991-03-20 | The Dow Chemical Company | 1,2,4-Triazolo[1,5-a]pyrimidine sulfonamides et compositions et méthodes pour contrôler la végétation non-désirable et supprimer la nitrification d'azote ammonium du sol |
AU567140B2 (en) * | 1984-01-06 | 1987-11-12 | Shionogi & Co., Ltd. | Sulphonamido-benzamide derivatives |
EP0154734B1 (fr) | 1984-03-15 | 1990-08-29 | Immunex Corporation | Essai pour la détection immédiate d'un ligand, trousse d'essai et sa préparation |
IT1196133B (it) * | 1984-06-06 | 1988-11-10 | Ausonia Farma Srl | Derivati furanici con attivita' antiulcera |
US4714693A (en) | 1986-04-03 | 1987-12-22 | Uop Inc. | Method of making a catalyst composition comprising uniform size metal components on carrier |
US5688655A (en) * | 1988-02-10 | 1997-11-18 | Ict Pharmaceuticals, Inc. | Method of screening for protein inhibitors and activators |
US5700637A (en) * | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
US6054270A (en) * | 1988-05-03 | 2000-04-25 | Oxford Gene Technology Limited | Analying polynucleotide sequences |
US5658775A (en) * | 1988-05-17 | 1997-08-19 | Sloan-Kettering Institute For Cancer Research | Double copy retroviral vector |
JP3082204B2 (ja) * | 1988-09-01 | 2000-08-28 | ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ | 両栄養性および環境栄養性宿主域を持つ組換え体レトロウイルス |
US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5744101A (en) * | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
US5143854A (en) * | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5527681A (en) * | 1989-06-07 | 1996-06-18 | Affymax Technologies N.V. | Immobilized molecular synthesis of systematically substituted compounds |
US5800992A (en) * | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
US5360822A (en) * | 1990-02-07 | 1994-11-01 | Nippon Shinyaku Co. Ltd. | Sulfonanilide derivatives and medicine |
AU7906691A (en) * | 1990-05-23 | 1991-12-10 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Adeno-associated virus (aav)-based eucaryotic vectors |
DE4022414A1 (de) | 1990-07-13 | 1992-01-16 | Bayer Ag | Substituierte pyrrolo-pyridine |
US5124335A (en) | 1991-01-30 | 1992-06-23 | Merck & Co., Inc. | Substituted pyrollo-fused 6 membered heterocycles as angiotensin ii antagonists |
WO1993002556A1 (fr) * | 1991-07-26 | 1993-02-18 | University Of Rochester | Therapie du cancer faisant appel a des cellules malignes |
US5632957A (en) * | 1993-11-01 | 1997-05-27 | Nanogen | Molecular biological diagnostic systems including electrodes |
FR2687402B1 (fr) * | 1992-02-14 | 1995-06-30 | Lipha | Nouveaux azaindoles, procedes de preparation et medicaments les contenant. |
JPH05236997A (ja) * | 1992-02-28 | 1993-09-17 | Hitachi Ltd | ポリヌクレオチド捕捉用チップ |
US5576319A (en) * | 1993-03-01 | 1996-11-19 | Merck, Sharp & Dohme Ltd. | Pyrrolo-pyridine derivatives |
BR9406128A (pt) * | 1993-03-01 | 1996-02-27 | Merck Sharp & Dohme | Uso de um composto processo para o tratamento e/ou prevençao de distúrbios psicóticos composto composiçao farmacêutica processos para a preparaçao de um composto e de uma composiçao farmacêutica |
ES2134929T3 (es) * | 1993-03-01 | 1999-10-16 | Merck Sharp & Dohme | Derivados de pirrolo-piridina como ligandos para receptores de dopamina. |
US5549614A (en) * | 1993-03-18 | 1996-08-27 | Tunis; Scott W. | Apparatus for folding flexible intraocular lenses |
ES2204921T3 (es) * | 1993-05-27 | 2004-05-01 | Selectide Corporation | Bibliotecas de fase solida codificadas, segregadas topologicamente. |
US5840485A (en) * | 1993-05-27 | 1998-11-24 | Selectide Corporation | Topologically segregated, encoded solid phase libraries |
US5631236A (en) * | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
US5426039A (en) * | 1993-09-08 | 1995-06-20 | Bio-Rad Laboratories, Inc. | Direct molecular cloning of primer extended DNA containing an alkane diol |
JP3545461B2 (ja) | 1993-09-10 | 2004-07-21 | エーザイ株式会社 | 二環式ヘテロ環含有スルホンアミド誘導体 |
US6045996A (en) * | 1993-10-26 | 2000-04-04 | Affymetrix, Inc. | Hybridization assays on oligonucleotide arrays |
US5965452A (en) * | 1996-07-09 | 1999-10-12 | Nanogen, Inc. | Multiplexed active biologic array |
US6468742B2 (en) * | 1993-11-01 | 2002-10-22 | Nanogen, Inc. | Methods for determination of single nucleic acid polymorphisms using bioelectronic microchip |
US5486525A (en) * | 1993-12-16 | 1996-01-23 | Abbott Laboratories | Platelet activating factor antagonists: imidazopyridine indoles |
US5807522A (en) * | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
US5763198A (en) * | 1994-07-22 | 1998-06-09 | Sugen, Inc. | Screening assays for compounds |
GB9416189D0 (en) | 1994-08-10 | 1994-09-28 | Merck Sharp & Dohme | Therapeutic agents |
GB9416162D0 (en) | 1994-08-10 | 1994-09-28 | Merck Sharp & Dohme | Therapeutic agents |
DE4430212A1 (de) * | 1994-08-28 | 1996-02-29 | Merck Patent Gmbh | Ortho-substituierte Benzoesäure-Derivate |
US5556752A (en) * | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
US5830645A (en) * | 1994-12-09 | 1998-11-03 | The Regents Of The University Of California | Comparative fluorescence hybridization to nucleic acid arrays |
GB2298199A (en) * | 1995-02-21 | 1996-08-28 | Merck Sharp & Dohme | Synthesis of azaindoles |
GB9503400D0 (en) | 1995-02-21 | 1995-04-12 | Merck Sharp & Dohme | Therpeutic agents |
US5959098A (en) * | 1996-04-17 | 1999-09-28 | Affymetrix, Inc. | Substrate preparation process |
US6117681A (en) * | 1995-03-29 | 2000-09-12 | Bavarian Nordic Research Inst. A/S | Pseudotyped retroviral particles |
GB2299581A (en) | 1995-04-07 | 1996-10-09 | Merck Sharp & Dohme | 3-(Tetrahydropyridin-1-yl-methyl)pyrrolo[2,3-b]pyridine derivatives as ligands for dopamine receptor subtypes |
GB9507291D0 (en) * | 1995-04-07 | 1995-05-31 | Merck Sharp & Dohme | Therapeutic agents |
US6110456A (en) * | 1995-06-07 | 2000-08-29 | Yale University | Oral delivery or adeno-associated viral vectors |
US5856174A (en) * | 1995-06-29 | 1999-01-05 | Affymetrix, Inc. | Integrated nucleic acid diagnostic device |
US5866411A (en) * | 1995-09-08 | 1999-02-02 | Pedersen; Finn Skou | Retroviral vector, a replication system for said vector and avian or mammalian cells transfected with said vector |
US5747276A (en) * | 1995-09-15 | 1998-05-05 | The Scripps Research Institute | Screening methods for the identification of novel antibiotics |
WO1997016533A1 (fr) * | 1995-10-31 | 1997-05-09 | The Regents Of The University Of California | Chromosomes mammaliens artificiels et procedes d'utilisation desdits chromosomes |
US6022963A (en) * | 1995-12-15 | 2000-02-08 | Affymetrix, Inc. | Synthesis of oligonucleotide arrays using photocleavable protecting groups |
US6013440A (en) * | 1996-03-11 | 2000-01-11 | Affymetrix, Inc. | Nucleic acid affinity columns |
US6025155A (en) * | 1996-04-10 | 2000-02-15 | Chromos Molecular Systems, Inc. | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
US5804585A (en) * | 1996-04-15 | 1998-09-08 | Texas Biotechnology Corporation | Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin |
PT948495E (pt) * | 1996-11-19 | 2004-08-31 | Amgen Inc | Agentes anti-inflamatorios de pirrolo fundido substituidos em arilo e heteroarilo |
US6294330B1 (en) * | 1997-01-31 | 2001-09-25 | Odyssey Pharmaceuticals Inc. | Protein fragment complementation assays for the detection of biological or drug interactions |
US6243980B1 (en) * | 1997-03-07 | 2001-06-12 | Tropix, Inc. | Protease inhibitor assay |
US5977131A (en) | 1997-04-09 | 1999-11-02 | Pfizer Inc. | Azaindole-ethylamine derivatives as nicotinic acetylcholine receptor binding agents |
US6096718A (en) * | 1997-06-05 | 2000-08-01 | Gene Targeting Corp. | Tissue specific adenovirus vectors for breast cancer treatment |
KR20010014183A (ko) | 1997-06-27 | 2001-02-26 | Fujisawa Pharmaceutical Co | 술폰아미드 화합물 및 그의 의약 용도 |
US6235769B1 (en) * | 1997-07-03 | 2001-05-22 | Sugen, Inc. | Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase |
US6826296B2 (en) * | 1997-07-25 | 2004-11-30 | Affymetrix, Inc. | Method and system for providing a probe array chip design database |
US6161776A (en) * | 1997-08-12 | 2000-12-19 | Nibco Inc. | Multi-layered, porous mat turf irrigation apparatus and method |
IL134702A (en) * | 1997-09-11 | 2004-03-28 | Bioventures Inc | High density arrays and methods of making the same |
US6178384B1 (en) * | 1997-09-29 | 2001-01-23 | The Trustees Of Columbia University In The City Of New York | Method and apparatus for selecting a molecule based on conformational free energy |
US6465178B2 (en) * | 1997-09-30 | 2002-10-15 | Surmodics, Inc. | Target molecule attachment to surfaces |
US6048695A (en) * | 1998-05-04 | 2000-04-11 | Baylor College Of Medicine | Chemically modified nucleic acids and methods for coupling nucleic acids to solid support |
US6288234B1 (en) * | 1998-06-08 | 2001-09-11 | Advanced Medicine, Inc. | Multibinding inhibitors of microsomal triglyceride transferase protein |
US6113913A (en) * | 1998-06-26 | 2000-09-05 | Genvec, Inc. | Recombinant adenovirus |
CN1261098C (zh) | 1998-08-28 | 2006-06-28 | 西奥斯股份有限公司 | p38-α激酶的抑制剂 |
US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
US6350786B1 (en) * | 1998-09-22 | 2002-02-26 | Hoffmann-La Roche Inc. | Stable complexes of poorly soluble compounds in ionic polymers |
US6277628B1 (en) * | 1998-10-02 | 2001-08-21 | Incyte Genomics, Inc. | Linear microarrays |
US6277489B1 (en) * | 1998-12-04 | 2001-08-21 | The Regents Of The University Of California | Support for high performance affinity chromatography and other uses |
US20010001449A1 (en) | 1998-12-30 | 2001-05-24 | Thomas R. Kiliany | Low-pressure hydrocracking process |
ES2219319T3 (es) * | 1999-03-17 | 2004-12-01 | Astrazeneca Ab | Derivados de amida. |
GB9906566D0 (en) | 1999-03-23 | 1999-05-19 | Zeneca Ltd | Chemical compounds |
US6221653B1 (en) * | 1999-04-27 | 2001-04-24 | Agilent Technologies, Inc. | Method of performing array-based hybridization assays using thermal inkjet deposition of sample fluids |
FR2793793B1 (fr) * | 1999-05-19 | 2004-02-27 | Adir | Nouveaux derives dimeriques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
TWI234557B (en) * | 1999-05-26 | 2005-06-21 | Telik Inc | Novel naphthalene ureas as glucose uptake enhancers |
US6653151B2 (en) * | 1999-07-30 | 2003-11-25 | Large Scale Proteomics Corporation | Dry deposition of materials for microarrays using matrix displacement |
US20010008765A1 (en) * | 1999-12-06 | 2001-07-19 | Fuji Photo Film Co., Ltd. | DNA chip and reactive solid carrier |
JP5004392B2 (ja) * | 1999-12-22 | 2012-08-22 | スージェン, インク. | インドリノン化合物を用いてc−kitチロシン蛋白質キナーゼ機能を調節する方法 |
NZ519380A (en) | 1999-12-28 | 2004-10-29 | Eisai Co Ltd | Heterocyclic compounds having sulfonamide groups |
JP2001278886A (ja) * | 2000-03-28 | 2001-10-10 | Dai Ichi Seiyaku Co Ltd | ベンゾオキサジン誘導体及びこれを含有する医薬 |
GB0007934D0 (en) * | 2000-03-31 | 2000-05-17 | Darwin Discovery Ltd | Chemical compounds |
JP4255285B2 (ja) | 2001-02-21 | 2009-04-15 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | インテグリン発現抑制を介した血管新生抑制剤の効果を検定する方法 |
CN101310771B (zh) | 2001-04-11 | 2012-08-08 | 千寿制药株式会社 | 视觉功能障碍改善剂 |
WO2002085896A1 (fr) | 2001-04-24 | 2002-10-31 | Wyeth | Derives azaheterocyclylmethyle antidepresseurs de 2,3-dihydro-1,4-benzodioxane |
GB0114417D0 (en) * | 2001-06-13 | 2001-08-08 | Boc Group Plc | Lubricating systems for regenerative vacuum pumps |
WO2002102783A1 (fr) | 2001-06-19 | 2002-12-27 | Merck & Co., Inc. | Inhibiteurs de la tyrosine kinase |
US7291639B2 (en) | 2001-06-20 | 2007-11-06 | Wyeth | Aryloxy-acetic acid compounds useful as inhibitors of plasminogen activator inhibitor-1 (PAI-1) |
GB0115109D0 (en) * | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
UA75425C2 (en) | 2001-07-09 | 2006-04-17 | Piperazine oxime derivatives with antagonistic activity to nk-1 receptor, use thereof, a pharmaceutical composition based thereon, a method for producing and a method for producing intermediary compounds | |
GB0117583D0 (en) | 2001-07-19 | 2001-09-12 | Astrazeneca Ab | Novel compounds |
US6858860B2 (en) * | 2001-07-24 | 2005-02-22 | Seiko Epson Corporation | Apparatus and method for measuring natural period of liquid |
GB0118479D0 (en) | 2001-07-28 | 2001-09-19 | Astrazeneca Ab | Novel compounds |
WO2003028724A1 (fr) | 2001-10-04 | 2003-04-10 | Smithkline Beecham Corporation | Inhibiteurs de la kinase chk1 |
JPWO2003037862A1 (ja) | 2001-10-30 | 2005-02-17 | 日本新薬株式会社 | アミド誘導体及び医薬 |
US20030236277A1 (en) | 2002-02-14 | 2003-12-25 | Kadow John F. | Indole, azaindole and related heterocyclic pyrrolidine derivatives |
US6884889B2 (en) | 2002-03-25 | 2005-04-26 | Bristol-Myers Squibb Co. | Processes for the preparation of antiviral 7-azaindole derivatives |
JP2005534619A (ja) | 2002-03-28 | 2005-11-17 | エーザイ株式会社 | C−junn−末端キナーゼ阻害剤としてのアザインドール |
IL164187A0 (en) | 2002-03-28 | 2005-12-18 | Eisai Co Ltd | 7-Azaindole derivatives and pharmaceutical compositions containing the same |
GB0212785D0 (en) * | 2002-05-31 | 2002-07-10 | Glaxo Group Ltd | Compounds |
UA78999C2 (en) | 2002-06-04 | 2007-05-10 | Wyeth Corp | 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6 |
TW200403243A (en) | 2002-07-18 | 2004-03-01 | Wyeth Corp | 1-Heterocyclylalkyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands |
TWI329112B (en) | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
US6878887B2 (en) * | 2002-08-07 | 2005-04-12 | Matsushita Electric Industrial Co., Ltd. | Anti-malfunction mechanism for variable output device |
SE0202463D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel compounds |
EP2277551B1 (fr) | 2002-09-06 | 2013-05-08 | Cerulean Pharma Inc. | Polymeres a base de cyclodextrine pour l'administration de medicament lies par liaison covalente |
US20040142864A1 (en) | 2002-09-16 | 2004-07-22 | Plexxikon, Inc. | Crystal structure of PIM-1 kinase |
DE60323133D1 (de) * | 2002-12-13 | 2008-10-02 | Smithkline Beecham Corp | Cyclohexylverbindungen als ccr5-antagonisten |
JP2006511554A (ja) * | 2002-12-13 | 2006-04-06 | スミスクライン ビーチャム コーポレーション | Ccr5アンタゴニストとしてのピペリジン誘導体 |
US7696225B2 (en) * | 2003-01-06 | 2010-04-13 | Osi Pharmaceuticals, Inc. | (2-carboxamido)(3-Amino) thiophene compounds |
SE0300120D0 (sv) | 2003-01-17 | 2003-01-17 | Astrazeneca Ab | Novel compounds |
SE0300119D0 (sv) | 2003-01-17 | 2003-01-17 | Astrazeneca Ab | Novel compounds |
US20050085463A1 (en) * | 2003-01-23 | 2005-04-21 | Weiner David M. | Use of N-desmethylclozapine to treat human neuropsychiatric disease |
CA2515571A1 (fr) * | 2003-02-14 | 2004-09-02 | Wyeth | Derives de heterocyclyl-3-sulfonylazaindole ou -azaindazole utilises comme ligands de la 5-hydroxytryptamine-6 |
US20050170431A1 (en) * | 2003-02-28 | 2005-08-04 | Plexxikon, Inc. | PYK2 crystal structure and uses |
US20050164300A1 (en) | 2003-09-15 | 2005-07-28 | Plexxikon, Inc. | Molecular scaffolds for kinase ligand development |
DE10357510A1 (de) | 2003-12-09 | 2005-07-07 | Bayer Healthcare Ag | Heteroarylsubstituierte Benzole |
PL1696920T3 (pl) | 2003-12-19 | 2015-03-31 | Plexxikon Inc | Związki i sposoby opracowywania modulatorów Ret |
GB0330043D0 (en) * | 2003-12-24 | 2004-01-28 | Pharmacia Italia Spa | Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them |
JP5697294B2 (ja) | 2003-12-24 | 2015-04-08 | デュポン ニュートリション バイオサイエンシーズ エーピーエス | 糖脂質アシル基転移酵素変異体及びその製造方法 |
GB0330042D0 (en) | 2003-12-24 | 2004-01-28 | Pharmacia Italia Spa | Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them |
GB0403635D0 (en) | 2004-02-18 | 2004-03-24 | Devgen Nv | Pyridinocarboxamides with improved activity as kinase inhibitors |
GB0405055D0 (en) | 2004-03-05 | 2004-04-07 | Eisai London Res Lab Ltd | JNK inhibitors |
ATE508129T1 (de) | 2004-03-30 | 2011-05-15 | Vertex Pharma | Als inhibitoren von jak und anderen proteinkinasen geeignete azaindole |
US7498342B2 (en) * | 2004-06-17 | 2009-03-03 | Plexxikon, Inc. | Compounds modulating c-kit activity |
CA2570817A1 (fr) * | 2004-06-17 | 2006-01-26 | Plexxikon, Inc. | Composes modulant l'activite de c-kit |
EP1765819B1 (fr) | 2004-06-30 | 2014-03-12 | Vertex Pharmaceuticals Inc. | Azaindoles utilises comme inhibiteurs de proteine kinases |
AU2005269387A1 (en) * | 2004-07-27 | 2006-02-09 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
US7626021B2 (en) * | 2004-07-27 | 2009-12-01 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
EP2264033A1 (fr) * | 2004-07-27 | 2010-12-22 | SGX Pharmaceuticals, Inc. | DÉRIVÉS PYRROLO[2,3b]PYRIDINE, 3,5-DIPHÉNYL SUBSTITUÉS, EN TANT QU'INHIBITEURS DE KINASES |
US7361764B2 (en) * | 2004-07-27 | 2008-04-22 | Sgx Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
US7709645B2 (en) * | 2004-07-27 | 2010-05-04 | Sgx Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
GB0419192D0 (en) * | 2004-08-27 | 2004-09-29 | Merck Sharp & Dohme | Therapeutic agents |
US8859581B2 (en) | 2005-04-25 | 2014-10-14 | Merck Patent Gmbh | Azaheterocyclic compounds as kinase inhibitors |
BRPI0610066A2 (pt) * | 2005-05-17 | 2010-05-25 | Plexxikon Inc | compostos que modulam atividade de c-kit e c-fms e usos para estes |
CN101228161B (zh) | 2005-05-20 | 2012-10-10 | 沃泰克斯药物股份有限公司 | 适用作蛋白激酶抑制剂的吡咯并吡啶类 |
BRPI0611863B1 (pt) * | 2005-06-22 | 2021-11-23 | Plexxikon, Inc | Composto, bem como composição e kit compreendendo o mesmo, composto intermediário na preparação do mesmo, método para tratamento e uso do mesmo |
GB0516156D0 (en) | 2005-08-05 | 2005-09-14 | Eisai London Res Lab Ltd | JNK inhibitors |
US20070218138A1 (en) * | 2006-03-20 | 2007-09-20 | Bittorf Kevin J | Pharmaceutical Compositions |
WO2008063888A2 (fr) * | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Composés modulant l'activité de c-fms et/ou de c-kit et utilisations associées |
WO2008079909A1 (fr) * | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Composés et méthodes de modulation des kinases, et indications connexes |
PE20121126A1 (es) * | 2006-12-21 | 2012-08-24 | Plexxikon Inc | Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa |
TW200908968A (en) * | 2007-05-29 | 2009-03-01 | Sgx Pharmaceuticals Inc | Substituted pyrrolopyridines and pyrazolopyridines as kinase modulators |
TW201041888A (en) * | 2009-05-06 | 2010-12-01 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
-
2006
- 2006-06-21 BR BRPI0611863-1A patent/BRPI0611863B1/pt active IP Right Grant
- 2006-06-21 RS RS20110485A patent/RS52010B/en unknown
- 2006-06-21 RU RU2011101140/04A patent/RU2565071C2/ru active
- 2006-06-21 ES ES11173701.1T patent/ES2565992T3/es active Active
- 2006-06-21 PE PE2006000690A patent/PE20070100A1/es active IP Right Grant
- 2006-06-21 US US11/473,347 patent/US7863288B2/en active Active
- 2006-06-21 EP EP16151919.4A patent/EP3088400A1/fr not_active Withdrawn
- 2006-06-21 TW TW103130685A patent/TWI522337B/zh active
- 2006-06-21 CA CA2613015A patent/CA2613015C/fr active Active
- 2006-06-21 CN CN201210012143.5A patent/CN102603581B/zh active Active
- 2006-06-21 TW TW102123382A patent/TWI473808B/zh active
- 2006-06-21 TW TW095122373A patent/TWI432193B/zh active
- 2006-06-21 KR KR1020087001659A patent/KR101125919B1/ko active Protection Beyond IP Right Term
- 2006-06-21 CN CN2006800303262A patent/CN101243084B/zh active Active
- 2006-06-21 EP EP06773861A patent/EP1893612B1/fr active Active
- 2006-06-21 SI SI200632039A patent/SI2395004T1/sl unknown
- 2006-06-21 CN CN201110084299.XA patent/CN102206216B/zh active Active
- 2006-06-21 UA UAA200800780A patent/UA95244C2/ru unknown
- 2006-06-21 WO PCT/US2006/024361 patent/WO2007002325A1/fr active Application Filing
- 2006-06-21 NZ NZ565255A patent/NZ565255A/en unknown
- 2006-06-21 EP EP11173701.1A patent/EP2395004B1/fr active Active
- 2006-06-21 DK DK11173701.1T patent/DK2395004T3/en active
- 2006-06-21 SI SI200631158T patent/SI1893612T1/sl unknown
- 2006-06-21 ES ES06773861T patent/ES2371397T3/es active Active
- 2006-06-21 WO PCT/US2006/024524 patent/WO2007002433A1/fr active Application Filing
- 2006-06-21 RU RU2008100933/04A patent/RU2418800C2/ru active Protection Beyond IP Right Term
- 2006-06-21 JP JP2008518402A patent/JP5007304B2/ja active Active
- 2006-06-21 AU AU2006261993A patent/AU2006261993B2/en active Active
- 2006-06-21 MY MYPI2011004969A patent/MY153898A/en unknown
- 2006-06-21 PT PT06773861T patent/PT1893612E/pt unknown
- 2006-06-21 PL PL11173701T patent/PL2395004T3/pl unknown
- 2006-06-21 HU HUE11173701A patent/HUE027370T2/en unknown
- 2006-06-21 MY MYPI20062939A patent/MY147410A/en unknown
- 2006-06-21 MX MX2007016463A patent/MX2007016463A/es active IP Right Grant
- 2006-06-21 DK DK06773861.7T patent/DK1893612T3/da active
- 2006-06-21 PL PL06773861T patent/PL1893612T3/pl unknown
- 2006-06-21 AT AT06773861T patent/ATE518860T1/de active
- 2006-06-22 AR ARP060102668A patent/AR054624A1/es active IP Right Grant
-
2007
- 2007-12-19 IL IL188248A patent/IL188248A/en active IP Right Grant
- 2007-12-20 ZA ZA2007/11152A patent/ZA200711152B/en unknown
- 2007-12-28 NO NO20076659A patent/NO333913B1/no active Protection Beyond IP Right Term
-
2008
- 2008-01-07 MA MA30548A patent/MA29612B1/fr unknown
- 2008-01-18 EC EC2008008121A patent/ECSP088121A/es unknown
- 2008-01-22 CR CR9677A patent/CR9677A/es unknown
- 2008-09-05 HK HK08109870.8A patent/HK1114610A1/xx unknown
-
2009
- 2009-11-10 US US12/616,079 patent/US8415469B2/en active Active
-
2010
- 2010-10-04 AR ARP100103601A patent/AR078519A2/es active IP Right Grant
- 2010-10-18 US US12/906,980 patent/US8470818B2/en active Active
-
2011
- 2011-08-23 US US13/216,200 patent/US8143271B2/en active Active - Reinstated
- 2011-09-23 US US13/243,748 patent/US20120053177A1/en not_active Abandoned
- 2011-11-03 CY CY20111101061T patent/CY1111996T1/el unknown
-
2012
- 2012-03-19 ZA ZA2012/02026A patent/ZA201202026B/en unknown
- 2012-03-19 ZA ZA2012/02025A patent/ZA201202025B/en unknown
- 2012-03-19 ZA ZA2012/02024A patent/ZA201202024B/en unknown
- 2012-06-07 HK HK12105582.9A patent/HK1164866A1/zh unknown
- 2012-06-26 DE DE201212000043 patent/DE122012000043I1/de active Pending
- 2012-06-26 HU HUS1200009C patent/HUS1200009I1/hu unknown
- 2012-06-28 LU LU92035C patent/LU92035I2/fr unknown
- 2012-07-31 CY CY2012021C patent/CY2012021I1/el unknown
- 2012-11-28 RU RU2012150759A patent/RU2629999C2/ru active
-
2013
- 2013-03-05 US US13/786,219 patent/US20130303534A1/en not_active Abandoned
- 2013-04-19 US US13/866,469 patent/US20130261117A1/en not_active Abandoned
- 2013-05-10 CR CR20130216A patent/CR20130216A/es unknown
-
2014
- 2014-03-20 NO NO2014006C patent/NO2014006I1/no not_active IP Right Cessation
-
2015
- 2015-01-21 US US14/602,119 patent/US20150290205A1/en not_active Abandoned
- 2015-07-13 US US14/798,167 patent/US20160176865A1/en not_active Abandoned
-
2017
- 2017-05-25 US US15/605,856 patent/US20180111929A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA29612B1 (fr) | Composes et methodes de modulation de la kinase et instructions afferentes | |
MA31153B1 (fr) | Composés et méthodes pour moduler une kinase et indications associées | |
MA31704B1 (fr) | Composés et compositions de 5-(4- (haloalkoxy) phényl) pyrimidine-2-amine utilisés comme inhibiteurs de kinases | |
MA30888B1 (fr) | Compositions et procedes de modulation de recepteurs de c-kit et de facteur de croissance derive de plaquettes (pdgfr) | |
MA28679B1 (fr) | Composes et compositions utilises comme inhibiteurs de proteines kinases | |
MA33604B1 (fr) | Composés et compositions en tant qu'inhibiteurs de protéine kinase | |
NO20091989L (no) | Forbindelser som modulerer c-fms og/eller C-kit aktivitet og deres anvendelse | |
Yu-Hai Chen et al. | The impact of family experience on the duration of untreated psychosis (DUP) in Hong Kong | |
MA29216B1 (fr) | Composes et compositions utilises comme inhibiteurs de la proteine kinase | |
MA30076B1 (fr) | Carbonylaminopyrrolopyrazoles servant de puissants inhibiteurs de kinases. | |
NO20061074L (no) | Forbindelser og sammensetninger som inbibitorer av reseptortyrosinkinaseaktivitet | |
MA31502B1 (fr) | Anticorps anti-notch 1 specifiques a nrr et ses procedes d'utilisation | |
MA30084B1 (fr) | Triazolopyridazines en tant que modulateurs de la tyrosine kinase | |
MA31764B1 (fr) | Composés et compositions en tant que modulateurs de l'activité de gpr119 | |
MA33241B1 (fr) | Composes pour le traitement de troubles metaboliques | |
MA31231B1 (fr) | Anticorps anti-robo4 et utilisations de ceux-ci | |
MA35460B1 (fr) | Composés et compositions en tant qu'inhibiteurs de kinase c-kit | |
BRPI0512422A (pt) | compostos e composições como inobidores da proteìna quinase | |
WO2008083238A3 (fr) | Agonistes de récepteur hétérocyclique pour le traitement du diabète et de troubles métaboliques | |
WO2006105516A3 (fr) | Compositions et procedes pour le diagnostic et le traitement de troubles neuropsychiatriques | |
EA201070012A1 (ru) | МЕТАБОЛИТЫ (R)-3-(4-(7H-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-1H-ПИРАЗОЛ-1-ИЛ)-3-ЦИКЛОПЕНТИЛПРОПАННИТРИЛА, ИНГИБИТОРА JANUS КИНАЗ | |
MA28583B1 (fr) | Dérivés de pyrimidine pour le traitement d'une croissance cellulaire anormale | |
MA30900B1 (fr) | Anticorps d'agonistes anti-notch3 et leur utilisation dans le traitement de maladies liées à notch3 | |
NO20082880L (no) | Inhibitorer av C-MET samt anvendelse derav | |
WO2010009342A3 (fr) | Inhibiteurs de tyrosine kinase de bruton pour le traitement de tumeurs solides |